Project Grant R21AA032100
- The National Institute on Alcohol Abuse and Alcoholism awarded The Johns Hopkins University $672,377 on September 20, 2025, under the Alcohol Research Programs (CFDA 93.273) to conduct a clinical trial assessing cannabidiol as an adjunct treatment for alcohol withdrawal and craving in patients with alcohol use disorder. The study recruits individuals with moderate-to-severe alcohol use disorder for a four-day inpatient investigation where participants are randomized to receive placebo solution...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $3.23 million Project Grant to The Regents of the University of Colorado (University of Colorado-Denver) on September 20, 2025, under the Alcohol Research Programs (CFDA 93.273). This four-year research project, concluding August 31, 2029, will investigate the effects of full-spectrum cannabidiol (CBD) on alcohol consumption and alcohol use disorder (AUD) phenotypes to inform precision medicine approaches. The research...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Regents of the University of Colorado $158,614 on June 1, 2026, under the Alcohol Research Programs grant program (CFDA 93.273) to conduct a randomized placebo-controlled trial exploring the effects of cannabidiol on sleep and alcohol use behaviors in adults reporting heavy drinking. The study will investigate cannabidiol as a treatment target for disrupted sleep in the context of alcohol use disorder, examining the...
- The National Institute on Alcohol Abuse and Alcoholism awarded San Diego State University Foundation $483,653 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate the effects of prenatal alcohol and cannabis exposure on vulnerability to later drug use disorders. The project uses a rodent model of prenatal alcohol, THC, or combined exposure via vapor inhalation to identify whether prenatal exposure causes long-lasting alterations in anxiety-like behaviors,...
- The National Institute on Alcohol Abuse and Alcoholism awarded Northwestern University $100,228 on December 18, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate projection-specific endocannabinoid signaling mechanisms in ethanol-related behaviors. The research examines how ethanol affects endocannabinoid-cannabinoid receptor type 1 signaling at dorsolateral striatum terminals in the external segment of the globus pallidus, and how altered signaling at these terminals...
- The National Institute on Drug Abuse awarded the University of California, San Diego $1,468,376 under the Drug Use and Addiction Research Programs (CFDA 93.279) on July 15, 2026, to conduct a prospective study characterizing sex-specific cannabinoid and endocannabinoid biomarkers as predictors of neuropsychological, behavioral, and withdrawal outcomes during cannabis abstinence in emerging adults. The research will recruit 220 participants aged 18–25 (balanced by sex, 64 percent with heavy...
- The National Institute on Drug Abuse awarded the University of California, San Diego $1,233,586 on September 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate epigenetic and neuroimmune mechanisms underlying cannabis-cannabinoid neuroimmunomodulation in people living with HIV. The recipient will conduct integrated clinical, postmortem, and mechanistic research examining how THC and CBD reshape the neuroimmune axis in people living with HIV through...
- The National Institute on Drug Abuse awarded The Johns Hopkins University $708,190 under the Drug Use and Addiction Research Programs (CFDA 93.279) on July 1, 2026, to conduct double-blind, placebo-controlled human laboratory studies examining the pharmacokinetic and pharmacodynamic effects of varying tetrahydrocannabinol (THC) and cannabidiol (CBD) ratios in cannabis edibles. Research Aim 1 will evaluate how different THC:CBD ratios—including 1:0, 1:1, 1:5, 1:10, 1:30, and 0:1—affect THC...
- The National Institute on Alcohol Abuse and Alcoholism awarded Texas A&M University System Health Science Center $635,002 on June 15, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate cholinergic modulation of striatal circuits in alcohol use disorder. The project examines how chronic alcohol intake affects acetylcholine signaling in the dorsomedial striatum, focusing on the interaction between direct-pathway medium spiny neurons and cholinergic interneurons. Research...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Regents of the University of California, San Francisco $613,750 on June 15, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate brain glucose metabolism dysfunction in alcohol use disorder. The research examines how alcohol activates the mTORC1 signaling pathway in dopamine D1 receptor-expressing neurons within the nucleus accumbens, leading to suppression of glycolytic enzymes including aldolase A and...
The National Institute on Alcohol Abuse and Alcoholism awarded the University of California, San Diego $190,000 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate the therapeutic potential of cannabidiol (CBD) in treating alcohol dependence by examining cellular and molecular mechanisms of CBD's effects on neuroadaptations in the basolateral amygdala. The research comprises two specific aims. Aim 1 determines the impact of chronic CBD treatment on GABAergic and glutamatergic transmission in basolateral amygdala neurons during acute alcohol withdrawal, including examination of withdrawal-induced FOS activation and cannabinoid receptor levels in both naive animals and those undergoing acute withdrawal. Aim 2 investigates long-term effects of CBD on the basolateral amygdala during protracted abstinence, exploring how CBD modulates alcohol-induced neuroadaptations in animals with a history of alcohol dependence in prolonged abstinence. The experiments employ electrophysiological recordings, RNA scope, and immunohistochemistry to elucidate cellular and molecular mechanisms underlying CBD's influence on alcohol-related neuroadaptations, with findings intended to inform development of novel therapeutic strategies for alcohol use disorders. Performance occurs in La Jolla, California. The period of performance runs from September 1, 2026, through May 31, 2028. The award is structured as a Project Grant, an assistance type supporting exploratory or developmental research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $190.0k | 9/2/26 |